These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 37638400)

  • 1. Patient-reported migraine-specific quality of life, activity impairment and headache impact with once-daily atogepant for preventive treatment of migraine in a randomized, 52-week trial.
    Lipton RB; Halker Singh RB; Mechtler L; McVige J; Ma J; Yu SY; Stokes J; Dabruzzo B; Gandhi P; Ashina M
    Cephalalgia; 2023 Aug; 51(8):3331024231190296. PubMed ID: 37638400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Atogepant for Preventive Migraine Treatment on Patient-Reported Outcomes in the Randomized, Double-blind, Phase 3 ADVANCE Trial.
    Lipton RB; Pozo-Rosich P; Blumenfeld AM; Li Y; Severt L; Stokes JT; Creutz L; Gandhi P; Dodick D
    Neurology; 2023 Feb; 100(8):e764-e777. PubMed ID: 36396451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atogepant for the Preventive Treatment of Migraine.
    Ailani J; Lipton RB; Goadsby PJ; Guo H; Miceli R; Severt L; Finnegan M; Trugman JM;
    N Engl J Med; 2021 Aug; 385(8):695-706. PubMed ID: 34407343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained response to atogepant in episodic migraine: post hoc analyses of a 12-week randomized trial and a 52-week long-term safety trial.
    Lipton RB; Nahas SJ; Pozo-Rosich P; Bilchik T; McAllister P; Finnegan M; Liu Y; Chalermpalanupap N; Dabruzzo B; Dodick DW
    J Headache Pain; 2024 May; 25(1):83. PubMed ID: 38773375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial.
    Tassorelli C; Nagy K; Pozo-Rosich P; Lanteri-Minet M; Sacco S; Nežádal T; Guo H; De Abreu Ferreira R; Forero G; Trugman JM
    Lancet Neurol; 2024 Apr; 23(4):382-392. PubMed ID: 38364831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atogepant: First Approval.
    Deeks ED
    Drugs; 2022 Jan; 82(1):65-70. PubMed ID: 34813050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and tolerability of atogepant for the preventive treatment of migraine: a post hoc analysis of pooled data from four clinical trials.
    Rizzoli P; Marmura MJ; Robblee J; McVige J; Sacco S; Nahas SJ; Ailani J; De Abreu Ferreira R; Ma J; Smith JH; Dabruzzo B; Ashina M
    J Headache Pain; 2024 Mar; 25(1):35. PubMed ID: 38462625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial.
    Schwedt TJ; Lipton RB; Ailani J; Silberstein SD; Tassorelli C; Guo H; Lu K; Dabruzzo B; Miceli R; Severt L; Finnegan M; Trugman JM
    Cephalalgia; 2022 Jan; 42(1):3-11. PubMed ID: 34521260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Atogepant in Chronic Migraine With and Without Acute Medication Overuse in the Randomized, Double-Blind, Phase 3 PROGRESS Trial.
    Goadsby PJ; Friedman DI; Holle-Lee D; Demarquay G; Ashina S; Sakai F; Neel B; Gandhi P; Dabruzzo B; Smith JH; Liu Y; Trugman JM
    Neurology; 2024 Jul; 103(2):e209584. PubMed ID: 38924724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rates of Response to Atogepant for Migraine Prophylaxis Among Adults: A Secondary Analysis of a Randomized Clinical Trial.
    Lipton RB; Pozo-Rosich P; Blumenfeld AM; Dodick DW; McAllister P; Li Y; Lu K; Dabruzzo B; Miceli R; Severt L; Finnegan M; Trugman JM
    JAMA Netw Open; 2022 Jun; 5(6):e2215499. PubMed ID: 35675076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Once-daily oral atogepant for the long-term preventive treatment of migraine: Findings from a multicenter, randomized, open-label, phase 3 trial.
    Ashina M; Tepper SJ; Reuter U; Blumenfeld AM; Hutchinson S; Xia J; Miceli R; Severt L; Finnegan M; Trugman JM
    Headache; 2023 Jan; 63(1):79-88. PubMed ID: 36651532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Single Supratherapeutic Dose of Atogepant Does Not Affect Cardiac Repolarization in Healthy Adults: Results From a Randomized, Single-Dose, Phase 1 Crossover Trial.
    Boinpally R; McNamee B; Yao L; Butler M; McGeeney D; Borbridge L; Periclou A
    Clin Pharmacol Drug Dev; 2021 Sep; 10(9):1099-1107. PubMed ID: 33942560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atogepant for Migraine Prevention: A Systematic Review of Efficacy and Safety.
    Singh A; Balasundaram MK
    Clin Drug Investig; 2022 Apr; 42(4):301-308. PubMed ID: 35230651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy, quality of life, safety, and tolerability of atogepant and rimegepant in migraine prevention: A matching-adjusted indirect comparison analysis.
    Tassorelli C; Onishchenko K; Halker Singh RB; Duan M; Dupont-Benjamin L; Hemstock M; Voller C; McAllister P; Nahas SJ; Gandhi P; Ailani J
    Cephalalgia; 2024 Feb; 44(2):3331024241235156. PubMed ID: 38410850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial.
    Goadsby PJ; Dodick DW; Ailani J; Trugman JM; Finnegan M; Lu K; Szegedi A
    Lancet Neurol; 2020 Sep; 19(9):727-737. PubMed ID: 32822633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small molecule CGRP receptor antagonists for the preventive treatment of migraine: A review.
    Dos Santos JBR; da Silva MRR
    Eur J Pharmacol; 2022 May; 922():174902. PubMed ID: 35358493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measures of Functioning in Patients With Episodic Migraine: Findings From a Double-Blind, Randomized, Placebo-Controlled Phase 2b Trial With Galcanezumab.
    Ayer DW; Skljarevski V; Ford JH; Nyhuis AW; Lipton RB; Aurora SK
    Headache; 2018 Sep; 58(8):1225-1235. PubMed ID: 30106172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and safety of atogepant for the prophylactic treatment of migraine: evidence from randomized controlled trials.
    Tao X; Yan Z; Meng J; Wang W; Dai Q; Zhou Q; Wang Z; Wang Z
    J Headache Pain; 2022 Jan; 23(1):19. PubMed ID: 35093013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atogepant Is Not Associated With Clinically Meaningful Alanine Aminotransferase Elevations in Healthy Adults.
    Min KC; Kraft WK; Bondiskey P; Colón-González F; Liu W; Xu J; Panebianco D; Mixson L; Dockendorf MF; Matthews CZ; Boinpally R
    Clin Transl Sci; 2021 Mar; 14(2):599-605. PubMed ID: 33142014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine-preventive medications in the phase 3b FOCUS study.
    Spierings ELH; Ning X; Ramirez Campos V; Cohen JM; Barash S; Buse DC
    Headache; 2021 Oct; 61(9):1376-1386. PubMed ID: 34374086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.